ePatientFinder has wrapped up an $8.2 million Series B round, giving it funds to expand the reach of its clinical trial enrollment platform.

Astellas has struck its third drug repurposing deal of the past six months. The latest collaboration sees Astellas start working with India's Excelra.

TwoXAR has teamed up with the University of Chicago to apply its software-driven approach to drug discovery to atherosclerosis.

Amgen and deCode have discovered a genetic variation associated with a 34% reduction in the risk of coronary artery disease in a trove of genome data.

Novartis has teamed up with UCSF and the Broad Institute to mine microbiome data in search of new classes of drugs.

A team of researchers has created a machine-learning tool to analyze failed chemical reactions and predict what combinations are likely to work in the future.

Yale School of Medicine has unveiled Hugo to make it easier for patients to contribute to research. The tool enables patients to share EHRs with researchers.

Intellia Therapeutics raised $108 million in an IPO, positioning it to invest upward of $10 million in technologies including its CRISPR informatics platform.